A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights.
clinical applications of TTFields
mechanisms of action of TTFields
tumor treating fields
Journal
Radiology and oncology
ISSN: 1581-3207
Titre abrégé: Radiol Oncol
Pays: Poland
ID NLM: 9317213
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
received:
20
07
2023
accepted:
04
08
2023
medline:
6
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Tumor Treating Fields (TTFields) is a non-invasive modality for cancer treatment that utilizes a specific sinusoidal electric field ranging from 100 kHz to 300 kHz, with an intensity of 1 V/cm to 3 V/cm. Its purpose is to inhibit cancer cell proliferation and induce cell death. Despite promising outcomes from clinical trials, TTFields have received FDA approval for the treatment of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM). Nevertheless, global acceptance of TTFields remains limited. To enhance its clinical application in other types of cancer and gain a better understanding of its mechanisms of action, this review aims to summarize the current research status by examining existing literature on TTFields' clinical trials and mechanism studies. Through this comprehensive review, we seek to stimulate novel ideas and provide physicians, patients, and researchers with a better comprehension of the development of TTFields and its potential applications in cancer treatment.
Sections du résumé
BACKGROUND
Tumor Treating Fields (TTFields) is a non-invasive modality for cancer treatment that utilizes a specific sinusoidal electric field ranging from 100 kHz to 300 kHz, with an intensity of 1 V/cm to 3 V/cm. Its purpose is to inhibit cancer cell proliferation and induce cell death. Despite promising outcomes from clinical trials, TTFields have received FDA approval for the treatment of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM). Nevertheless, global acceptance of TTFields remains limited. To enhance its clinical application in other types of cancer and gain a better understanding of its mechanisms of action, this review aims to summarize the current research status by examining existing literature on TTFields' clinical trials and mechanism studies.
CONCLUSIONS
Through this comprehensive review, we seek to stimulate novel ideas and provide physicians, patients, and researchers with a better comprehension of the development of TTFields and its potential applications in cancer treatment.
Identifiants
pubmed: 37665740
pii: raon-2023-0044
doi: 10.2478/raon-2023-0044
pmc: PMC10476910
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
279-291Informations de copyright
© 2023 Xing Li et al., published by Sciendo.
Références
J Clin Oncol. 1999 Aug;17(8):2572-8
pubmed: 10561324
IEEE Trans Biomed Eng. 2020 Sep;67(9):2594-2602
pubmed: 31940516
Lab Chip. 2013 Oct 7;13(19):3803-21
pubmed: 23917998
Cancer Immunol Immunother. 2020 Jul;69(7):1191-1204
pubmed: 32144446
Int J Cancer. 2016 Dec 15;139(12):2850-2858
pubmed: 27561100
Lung Cancer. 2021 Oct;160:99-110
pubmed: 34482104
Biosystems. 2004 Nov;77(1-3):73-85
pubmed: 15527947
Cell Death Discov. 2022 Oct 11;8(1):416
pubmed: 36220835
Front Oncol. 2020 Oct 30;10:575992
pubmed: 33215030
Cell Death Dis. 2017 Apr 20;8(4):e2753
pubmed: 28425987
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
BMC Med Phys. 2009 Jan 08;9:1
pubmed: 19133110
Clin Exp Metastasis. 2009;26(7):633-40
pubmed: 19387848
PLoS One. 2015 May 26;10(5):e0125269
pubmed: 26010837
Biomicrofluidics. 2010 Jun 29;4(2):
pubmed: 20697589
J Vis Exp. 2019 Apr 16;(146):
pubmed: 31058901
Lancet Oncol. 2019 Dec;20(12):1702-1709
pubmed: 31628016
Neuro Oncol. 2016 Oct;18(10):1338-49
pubmed: 27664860
Eur J Cancer. 2012 Sep;48(14):2192-202
pubmed: 22608262
Phys Rev E Stat Nonlin Soft Matter Phys. 2002 Jul;66(1 Pt 1):011901
pubmed: 12241378
Biophys J. 1998 May;74(5):2689-701
pubmed: 9591693
Lung Cancer. 2013 Sep;81(3):445-450
pubmed: 23891283
Int J Environ Res Public Health. 2016 Nov 12;13(11):
pubmed: 27845746
Adv Exp Med Biol. 2016;893:1-19
pubmed: 26667336
Cancers (Basel). 2019 Dec 12;11(12):
pubmed: 31842288
Pancreatology. 2019 Jan;19(1):64-72
pubmed: 30396819
Cancer Res. 2004 May 1;64(9):3288-95
pubmed: 15126372
Semin Oncol Nurs. 2018 May;34(2):137-150
pubmed: 29631935
Sci Rep. 2019 May 14;9(1):7362
pubmed: 31089145
Sci Rep. 2019 Dec 10;9(1):18699
pubmed: 31822748
Cell Death Discov. 2018 Dec 5;4:113
pubmed: 30534421
Sci Rep. 2015 Dec 11;5:18046
pubmed: 26658786
Tissue Eng Part B Rev. 2023 Jun;29(3):217-231
pubmed: 36170583
JAMA. 2015 Dec 15;314(23):2535-43
pubmed: 26670971
Bioelectromagnetics. 2020 Sep;41(6):438-446
pubmed: 32515015
Cell Death Dis. 2018 Oct 19;9(11):1074
pubmed: 30341282
Neuro Oncol. 2016 Mar;18(3):303-5
pubmed: 26917587
Clin Cancer Res. 2018 Jan 15;24(2):266-275
pubmed: 28765323
Biochem Biophys Res Commun. 2002 Apr 26;293(1):602-9
pubmed: 12054645
Nat Rev Cancer. 2014 Mar;14(3):199-208
pubmed: 24561446
Oncogene. 2019 Sep;38(39):6630-6646
pubmed: 31375748
Transl Oncol. 2022 Jan;15(1):101296
pubmed: 34847422
Cancers (Basel). 2019 Jan 18;11(1):
pubmed: 30669316
J Clin Oncol. 2023 May 20;41(15):2682-2690
pubmed: 37196429
Heliyon. 2023 Apr 04;9(4):e15195
pubmed: 37089335
Pancreatology. 2014 Jan-Feb;14(1):54-63
pubmed: 24555979
Nat Rev Clin Oncol. 2015 Jun;12(6):319-34
pubmed: 25824606
Adv Radiat Oncol. 2021 May 17;6(4):100716
pubmed: 34409211
Biochem Biophys Res Commun. 1988 Sep 30;155(3):1464-70
pubmed: 3178822
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
J Cell Biol. 1991 May;113(4):805-15
pubmed: 2026651
Cell Death Discov. 2018 Jul 16;4:12
pubmed: 30210815
J Clin Invest. 2022 Apr 15;132(8):
pubmed: 35199647
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Gynecol Oncol. 2018 Sep;150(3):471-477
pubmed: 30060963
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7
pubmed: 17551011
Lancet Oncol. 2014 Jul;15(8):799-808
pubmed: 24950985
Ann N Y Acad Sci. 2013 Jul;1291:86-95
pubmed: 23659608
Cancers (Basel). 2022 Jun 15;14(12):
pubmed: 35740624
Transl Res. 2020 Mar;217:33-46
pubmed: 31707040